| Ytd | 36.85% | |
| 1y | 169.02% |
| Open | 26.03 | Prev Close | 25.88 | Low | 25.46 | High | 26.36 | Mkt Cap | 2.69B |
| Vol | 0.00 | Avg Vol | 2.03M | EPS | -3.45 | P/E | -7.52 | Forward P/E | -17.74 |
| Beta | 1.79 | Short Ratio | 7.71 | Inst. Own | 112.94% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-08 | 50-d Avg | 21.30 | 200-d Avg | 17.54 | 1yr Est | 33.31 |
Nurix Therapeutics, Inc. (NASDAQ: NRIX - Get Free Report)'s stock price hit a new 52-week high durin
RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform a
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the d
Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has ea
Phase 3 trial designed to demonstrate superiority of bexobrutideg versus pirtobrutinib in patients w
Morgan Stanley analyst Terence Flynn maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight
RHHBY posts 6% constant-currency sales growth in the first half of 2026 as strong demand for key dru
UBS analyst David Dai maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price
Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is
Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is
Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is
BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clini
Amova Asset Management Americas Inc. cut its position in shares of Nurix Therapeutics, Inc. (NASDAQ:
Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by
Mizuho analyst Joseph Catanzaro maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.81 per share versus the Zacks C
Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up t
Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a lik
The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 29.2% upside in the st
Health care stocks flashing warning to momentum investors. RSI indicator shows overbought for DFTX,
NRIX rallies on its collaboration with Roche for bexobrutideg, featuring a $700 million upfront paym
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher
Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday'
Recently, Nurix secured a partnership with Roche, which I believe has substantially derisked the sto
High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor
Nurix Therapeutics, Inc. remains a Strong Buy as bexobrutideg advances in pivotal r/r CLL trials and
Wall Street analysts change outlook on top names. B of A cuts CPB, UBS cuts AJG PT, B of A boosts OR
Nurix Therapeutics (NRIX) was a big mover last session on higher-than-average trading volume. The la
Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercializat
Roche Holding AG (RHHBY) has agreed to pay Nurix Therapeutics (NRIX) as much as $2.3 billion for rig
Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding pot
href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-th
On Wednesday, 311 stocks hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
During Thursday's session, 406 companies made new 52-week lows.
On Wednesday, 179 companies reached new 52-week lows.
On Wednesday, 807 companies reached new 52-week lows.
During Wednesday's trading, 435 companies set new 52-week lows.